Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 5/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13653104 | 0.88 | HDAC8 (0.54) | NPY5RHDAC8NAMPTTRPV1HDAC1 | |
| SCHEMBL4188741 | 0.88 | HDAC1 (0.45) | NPY5RHDAC8NAMPTTRPV1HDAC1 | |
| SCHEMBL13653164 | 0.86 | KMT2A (0.41) | NPY5RHDAC8NAMPTTRPV1POLB | |
| SCHEMBL4190946 | 0.86 | HDAC1 (0.50) | HDAC8NAMPTHDAC1KCNH2CYP3A4 | |
| SCHEMBL5186028 | 0.81 | HDAC8 (0.40) | NPY5RHDAC8NAMPTHDAC1KCNH2 | |
| SCHEMBL13653136 | 0.81 | CA12 (0.45) | TRPV1MEN1KMT2ANPY1R | |
| SCHEMBL4185804 | 0.81 | PDE4A (0.44) | TRPV1MEN1KMT2ANPY1R | |
| SCHEMBL13653130 | 0.80 | NAMPT (0.44) | NAMPTTRPV1HDAC1NPY1R | |
| SCHEMBL13653140 | 0.79 | NPY1R (0.41) | HDAC1NPY1R | |
| SCHEMBL27707651 | 0.79 | NPY5R (0.39) | NPY5RHDAC8KCNH2POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247590-A1 | Indane amides | MKI67, PPIP5K2, CCNA1 | NPY5R 2016/4885HDAC8 191/4885NAMPT 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.